Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
Jason R. Clapper(Amplyx Pharmaceuticals (United States)), Jonathan D. Roth(Rutgers, The State University of New Jersey), Guibao Gu(Arena Pharmaceuticals (United States)), Jennifer Athanacio(Amplyx Pharmaceuticals (United States)), Christiane Villescaz(Amplyx Pharmaceuticals (United States)), John Herich(Amplyx Pharmaceuticals (United States)), Joseph S. Heilig(Amplyx Pharmaceuticals (United States)), Carrie S. Dolman(Amplyx Pharmaceuticals (United States)), Soumitra S. Ghosh(Amplyx Pharmaceuticals (United States)), Michelle D. Hendricks(Amplyx Pharmaceuticals (United States)), Carolyn Lowe(The University of Texas at San Antonio Health Science Center), Carrie Wittmer(Amplyx Pharmaceuticals (United States))
American Journal of Physiology-Gastrointestinal and Liver Physiology
July 26, 2013
Cited by 294
Related Papers
Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
|Proceedings of the National Academy of Sciences|2008|433
Amylin: Pharmacology, Physiology, and Clinical Potential
|Pharmacological Reviews|2015|395
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
|Nature Neuroscience|2010|348
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
|American Journal of Physiology-Gastrointestinal and Liver Physiology|2012|278